| [1] |
赵雪，宋蕊．自然杀伤细胞在感染中的研究进展[J/CD]．中华实验和临床感染病杂志(电子版)，2019, 13(2):93-98.
|
| [2] |
吴玲，郜玉峰，苏菲．NK/NKT细胞在乙型肝炎发病机制中的研究进展[J]．国际流行病学传染病学杂志，2010, 37(1):64-67.
|
| [3] |
Miller JS. Therapeutic applications: natural killer cells in the clinic[J]. Hematology Am Soc Hematol Educ Program, 2013:247-253.
|
| [4] |
邹勇，郑常龙，杨小安．HBV-ACLF患者外周血和肝脏IL-32的表达水平与肝损伤的相关性[J]．新医学，2018, 49(2):94-98.
|
| [5] |
曾永秦，逄晓莉，汪笛，等．NK细胞在HIV感染中的作用:进展和展望[J]．传染病信息，2018, 31(6):566-571.
|
| [6] |
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer[J]. Scientifica, 2014:205796.
|
| [7] |
Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells[J]. Adv Immunol, 2014(122): 91-128.
|
| [8] |
Dahlberg C, Sarhan D, Chrobok M, et al. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity [J]. Front Immunol, 2015(6):605.
|
| [9] |
Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy[J]. Front Immunol, 2015(6):601.
|
| [10] |
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer, 2015, 16(1):7-19.
|
| [11] |
Li Y, Yin J, Li T, et al. NK cell-based cancer immunotherapy: from basic biology to clinical application[J]. Sci China Life Sci, 2015, 58(12):1233-1245.
|
| [12] |
刘琳琳，聂汉祥．恒定自然杀伤细胞在感染免疫中的作用研究进展[J]．疑难病杂志，2016, 15(5):546-549.
|
| [13] |
李文静，张栋，顾绍庆．自然杀伤细胞受体与人巨细胞病毒感染的研究进展[J]．国际儿科学杂志，2015, 42(4):377-380.
|
| [14] |
Benson DM Jr, Cohen AD, Jagannath S, et al. A phaseⅠtrial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma[J]. Clin Cancer Res, 2015, 21(18):4055-4061.
|
| [15] |
Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity[J]. Front Immunol, 2015(6): 195.
|
| [16] |
Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells[J]. Front Pharmacol, 2015(6): 21.
|
| [17] |
Szmania S, Lapteva N, Garg T, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients[J]. J Immunother, 2015, 38(1):24-36.
|
| [18] |
Sakamoto N, Ishikawa T, Kokura S, et al. PhaseⅠclinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer[J]. J Transl Med, 2015(13):277.
|
| [19] |
Oyer JL, Pandey V, Igarashi RY, et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment[J]. Cytotherapy, 2016, 18(5):653-663.
|
| [20] |
Kottaridis PD, North J, Tsirogianni M, et al. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase Ⅰ trial[J]. PLoS One, 2015, 10(6): e0123416.
|